'Clinical validation' presentation slideshows

CIMI Modelling Taskforce Report

CIMI Modelling Taskforce Report. Dr Linda Bird 14 th May 2012. Agenda. Members Mission & TOR Overview of work Call For Models Modelling Approach Background Foundations Summary of Approach. Taskforce Members. Technical Resources: Peter Hendler Galen Mulrooney Grahame Grieve

862 views • 73 slides

Gene Pennello, Ph.D. Team Leader, Diagnostics Devices Branch Division of Biostatistics

Clinical Validation of Prognostic Biomarkers of Risk and Predictive Biomarkers of Drug Efficacy or Safety. Gene Pennello, Ph.D. Team Leader, Diagnostics Devices Branch Division of Biostatistics Office of Surveillance and Biometrics Center for Devices and Radiological Health, FDA.

853 views • 72 slides

Neuro -QOL: Health-Related Quality of Life Measures for Neurology Research and Practice

Neuro -QOL: Health-Related Quality of Life Measures for Neurology Research and Practice. Claudia Scala Moy, PhD Office of Clinical Research National Institute of Neurological Disorders and Stroke. Disclosures. No financial disclosures

908 views • 70 slides

Molecular Pathology and the Molecular Diagnostics Lab

3.13k views • 61 slides

Molecular Pathology and the Molecular Diagnostics Lab

921 views • 61 slides

On approaches to ameliorate the insidious and pernicious problem of interference and inaccuracy in immunoassays

On approaches to ameliorate the insidious and pernicious problem of interference and inaccuracy in immunoassays. Adel A.A.Ismail. To discuss the following. How common. Suspecting interference. Current follow-up confirmatory tests and their limitations.

629 views • 45 slides

Anatomy of an Appeal

Anatomy of an Appeal. Michelle A. Barrett, JD, RN mianbarrett@yahoo.com April 13, 2019. Learning Objectives. B egin to understand the procedural flow of denials and appeals Navigate the nuances of various payers Understand medical record review for appeal writing

348 views • 34 slides

Pharmacogenetics in the treatment of breast and ovarian cancer patients

Pharmacogenetics in the treatment of breast and ovarian cancer patients. Peter A. Fasching. UCLA. David Geffen School of Medicine Div. Hem/Onc. Concepts of science. Therapy A. Therapy B. Therapy A must be better. Pitfalls with this approach. Will this patient have a recurrence?.

548 views • 29 slides

Cathy Tralau -Stewart PhD Head of Drug Discovery Drug Discovery Centre Imperial College

The Imperial Drug Discovery Centre; enabling translation of academic projects towards clinical validation. Cathy Tralau -Stewart PhD Head of Drug Discovery Drug Discovery Centre Imperial College www.imperial.ac.uk /medicine/ drugdiscoverycentre. Drug Discovery Landscape.

563 views • 26 slides

Neuroscience Biomarker Program

Neuroscience Biomarker Program. Mary Ann Pelleymounter, PhD Program Director mary.pelleymounter@nih.gov Victoria Smith, PhD Health Program Specialist victoria.smith@nih.gov. Advancing a Biomarker Candidate from Discovery Through Qualification. Laboratory. Clinical Use.

285 views • 19 slides

Alliance of Glycobiologists for Detection of Cancer and Cancer Risk

Alliance of Glycobiologists for Detection of Cancer and Cancer Risk. Karl Krueger, Ph.D. Division of Cancer Prevention. Web Cast Links. URL: http://videocast.nih.gov Presentation slides: http://www.cancer.gov/edrn

328 views • 17 slides